CO5640064A2 - Citomodilacion de peptidos para tratar cistitis intersticial - Google Patents
Citomodilacion de peptidos para tratar cistitis intersticialInfo
- Publication number
- CO5640064A2 CO5640064A2 CO05057644A CO05057644A CO5640064A2 CO 5640064 A2 CO5640064 A2 CO 5640064A2 CO 05057644 A CO05057644 A CO 05057644A CO 05057644 A CO05057644 A CO 05057644A CO 5640064 A2 CO5640064 A2 CO 5640064A2
- Authority
- CO
- Colombia
- Prior art keywords
- amino acid
- interstitial cystitis
- citomodilation
- peptides
- amino acids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
1.- Un método para tratar cistitis intersticial, que comprende: administrar a un sujeto afectado una cantidad farmacéuticamente efectiva de una composición que comprende un oligopéptido RDP58.2.- El método de la reivindicación 1, en donde el oligopéptido RDP58 consiste de la secuencia de aminoácido: Arg-nL-nL-nL-Arg-nL-nL-nL-Gly-Tyr.3.- El método de la reivindicación 1, en donde al menos uno de los aminoácidos terminales es un aminoácido modificado.4.- El método de la reivindicación 3, en donde el aminoácido modificado es un aminoácido amidatado o sales de éste.5.- El método de la reivindicación 1, en donde uno o más de los aminoácidos son isómeros D.6.- El método de la reivindicación 5, en donde todos los aminoácidos son el isómero D.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42668402P | 2002-11-15 | 2002-11-15 | |
| US47083903P | 2003-05-15 | 2003-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5640064A2 true CO5640064A2 (es) | 2006-05-31 |
Family
ID=32329122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05057644A CO5640064A2 (es) | 2002-11-15 | 2005-06-14 | Citomodilacion de peptidos para tratar cistitis intersticial |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7671026B2 (es) |
| EP (1) | EP1594519A4 (es) |
| JP (1) | JP2006516546A (es) |
| KR (1) | KR20050086676A (es) |
| AU (1) | AU2003294357A1 (es) |
| BR (1) | BR0316290A (es) |
| CA (1) | CA2505922A1 (es) |
| CO (1) | CO5640064A2 (es) |
| MA (1) | MA27607A1 (es) |
| MX (1) | MXPA05005101A (es) |
| NO (1) | NO20052814L (es) |
| RU (1) | RU2005118425A (es) |
| WO (1) | WO2004045554A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2069791B1 (en) * | 2006-07-27 | 2012-01-25 | University of Maryland, Baltimore | Cellular receptor for antiproliferative factor |
| DK2252627T3 (en) * | 2008-01-24 | 2017-08-14 | Esperance Pharmaceuticals | MERGER CONSTRUCTION WITH LYTIC DOMAIN AND METHOD FOR PRODUCING AND USING SAME. |
| AU2009282625A1 (en) * | 2008-08-18 | 2010-02-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Derivatives of APF and methods of use |
| JP5857056B2 (ja) | 2010-10-14 | 2016-02-10 | ザイジェン インフラメーション エルティーディー | 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用 |
| WO2014204988A2 (en) | 2013-06-17 | 2014-12-24 | Asana Biosciences, Llc | 5t4-targeted immunofusion molecule and methods |
| WO2015197194A2 (en) * | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2014206426A1 (en) * | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| US10859579B2 (en) * | 2016-03-31 | 2020-12-08 | William Beaumont Hospital | Methods for detecting, diagnosing and treating ulcerative interstitial cystitis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696545B1 (en) * | 1997-04-11 | 2004-02-24 | Sangstat Medical Corporation | Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation |
| CN1216900C (zh) * | 1997-04-11 | 2005-08-31 | 桑斯塔特医学有限公司 | 用于调节免疫系统活性和抑制炎症的细胞调节性亲脂肽 |
| JP2002512259A (ja) * | 1998-04-17 | 2002-04-23 | ユニバーシティ・オブ・メリーランド， ボルティモア | 組換えヘパリン結合性上皮成長因子様成長因子（ｈｂ−ｅｇｆ）による間質性膀胱炎の治療方法 |
| PL374700A1 (en) * | 2002-09-20 | 2005-10-31 | Alcon, Inc. | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
-
2003
- 2003-11-17 RU RU2005118425/14A patent/RU2005118425A/ru not_active Application Discontinuation
- 2003-11-17 MX MXPA05005101A patent/MXPA05005101A/es not_active Application Discontinuation
- 2003-11-17 EP EP03789840A patent/EP1594519A4/en not_active Ceased
- 2003-11-17 JP JP2004570638A patent/JP2006516546A/ja active Pending
- 2003-11-17 CA CA002505922A patent/CA2505922A1/en not_active Abandoned
- 2003-11-17 WO PCT/US2003/037043 patent/WO2004045554A2/en active Application Filing
- 2003-11-17 BR BR0316290-7A patent/BR0316290A/pt not_active Application Discontinuation
- 2003-11-17 US US10/535,167 patent/US7671026B2/en not_active Expired - Fee Related
- 2003-11-17 KR KR1020057008774A patent/KR20050086676A/ko not_active Application Discontinuation
- 2003-11-17 AU AU2003294357A patent/AU2003294357A1/en not_active Abandoned
-
2005
- 2005-06-10 NO NO20052814A patent/NO20052814L/no unknown
- 2005-06-14 MA MA28336A patent/MA27607A1/fr unknown
- 2005-06-14 CO CO05057644A patent/CO5640064A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006516546A (ja) | 2006-07-06 |
| AU2003294357A1 (en) | 2004-06-15 |
| EP1594519A2 (en) | 2005-11-16 |
| EP1594519A4 (en) | 2006-08-16 |
| KR20050086676A (ko) | 2005-08-30 |
| MXPA05005101A (es) | 2005-09-08 |
| WO2004045554A2 (en) | 2004-06-03 |
| MA27607A1 (fr) | 2005-11-01 |
| BR0316290A (pt) | 2005-10-11 |
| NO20052814D0 (no) | 2005-06-10 |
| RU2005118425A (ru) | 2006-02-10 |
| NO20052814L (no) | 2005-08-04 |
| US7671026B2 (en) | 2010-03-02 |
| CA2505922A1 (en) | 2004-06-03 |
| US20060194738A1 (en) | 2006-08-31 |
| WO2004045554A3 (en) | 2005-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5640064A2 (es) | Citomodilacion de peptidos para tratar cistitis intersticial | |
| AR018501A1 (es) | Derivados de la dolastatina 15 | |
| PE20061427A1 (es) | Metodos para identificar objetivos terapeuticos para el tratamiento de la atrofia vulvovaginal | |
| AR042545A1 (es) | Agentes ligantes que inhiben la miostatina | |
| ES2031826T3 (es) | Procedimiento para producir nuevos peptidos activadores del plasminogeno. | |
| ES2170884T3 (es) | Acidos alfa-iminohidroxamicos y carboxilicos n-sustituidos, ciclicos y heterociclicos. | |
| CO5700785A2 (es) | Composiciones inmunogenicas novedosas para la prevencion y el tratamiento de enfermedad meningococal | |
| UY28280A1 (es) | 2- hidroxi - 3- diaminoalcanos de benzamida | |
| ATE450269T1 (de) | Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten | |
| CY1111225T1 (el) | Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c | |
| RU94015838A (ru) | Производные бензофуранил- или бензотиофенилалкан-карбоновой кислоты, смесь их изомеров или отдельные изомеры и их соли | |
| JPH02138300A (ja) | 南アメリカ蛭ハエメンテリアギリアニからの抗凝固剤精の抽出及び精製 | |
| Selistre et al. | Isolation and characterization of hemorrhagic, myonecrotic and edema-inducing toxins from Bothrops insularis (jararaca ilhoa) snake venom | |
| ES2137182T3 (es) | Derivados recombinantes del factor viii humano. | |
| DE69626517D1 (de) | Methode zur behandlung der corticosteroid-induzierten orteopenie | |
| DOP2003000765A (es) | Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer (substituted ureas and carbamates useful in the treatment of alzheimer`s disease | |
| DE69410254D1 (de) | Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente | |
| ATE292801T1 (de) | Verfahren zum screening von inhibitoren von asp2 | |
| BR0208052A (pt) | Composição que inibe matriz metaloproteinases para o tratamento de doenças neoplásicas | |
| DK384084A (da) | Vaeksthormonfrigoerende peptider samt fremgangsmaade til behandling af pattedyr hermed | |
| ATE377026T1 (de) | Behandlung von fettleibigkeit | |
| ES2124983T3 (es) | Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno. | |
| ECSP077169A (es) | Métodos para mejorar la biodisponibilidad de un inhibidor de renina | |
| IS5239A (is) | Notkun á hliðstæðum gamma-amínósmjörsýru (GABA) áborð við GABA-pentín til vinnslu lyfs til meðferðar á bólgusjúkdómum | |
| Saric et al. | Non-covalent interaction of ubiquitin with insulin-degrading enzyme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |